Development-stage specialty pharmaceutical company Tonix Pharmaceuticals Holding Corp. announced it has become a corporate partner of the American Chronic Pain Association (ACPA) as part of that organization’s efforts to raise awareness about fibromyalgia, a syndrome increasingly identified in people who suffer chronic pain and believed to affect around 5 million people in the United States.

Currently, Tonix is developing TNX-102 SL, its lead clinical candidate for treating fibromyalgia and post-traumatic stress disorder. Tonix recently announced the initiation of the BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) clinical trial – the first of two anticipated pivotal trials for TNX-102 SL 2.8 mg tablets in patients with fibromyalgia.

“We continue to strive to provide the best possible support, education in pain management skills, and resources to those who experience chronic pain in whatever form it takes,” said ACPA Executive Director and FounderPenney Cowan. “Partnerships with companies such as Tonix provide us with an important opportunity to inform consumers about the many elements of multidisciplinary pain management so that they may regain a sense of control in their lives and hope for their future.”

In April 2013, fibromyalgia was selected by the FDA as a disease to focus on for the next two fiscal years. A public meeting will be conducted by the FDA on Dec. 10, 2013 under Patient-Focused Development, an initiative involving acquisition of a better understanding of patients’ perspectives on the severity of the disease and available therapies for the condition. These activities are demonstrative of an increased awareness of fibromyalgia and its impact in the U.S. population.

For more information, visit www.tonixpharma.com or www.theacpa.org

Let us hear your thoughts below: